Active — Not RecruitingNot Applicable

Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer

Germany40 participantsStarted 2022-11-30

Plain-language summary

This pilot study aims to trial multimodal early response assessment to enable therapy adaptions in the context of non-operative therapy strategies of locally advanced rectal cancer (LARC) for development of a non-invasive response prediction model.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * locally advanced rectal cancer (LARC): UICC Stage II/III * no severe cardiac or lung disease * no severe hepatic disorders (liver enzymes \<2.5 NR) or restrictions of renal function (GFR \> 30ml/min) * no severe cytopenia (Neutrocytes \>= 3 Gpt/l; Thrombocytes \>= 100 Gpt/l; Hemoglobin \>6mmol/l) * no homozygotic DPD deficiency * no other neoplasms requiring therapy * no earlier radiotherapy of the pelvis or earlier chemotherapy * no contraindications for MRI

What they're measuring

Tumor regression grading (TRG)

Timeframe: after completion of neoadjuvant treatment (up to 10 months)

Trial details

NCT IDNCT05524012

SponsorJena University Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-01-31

View on ClinicalTrials.gov More Locally Advanced Rectal Carcinoma trials